Pre-Close Trading Update
19 January 2011
Instem Life Science Systems plc
("Instem", the "Company" or the "Group")
Pre-Close Trading Update
Instem Life Science Systems plc (AIM:INS.L), a leading provider of IT applications to the global early development healthcare market, is pleased to give an update on trading for the year ended 31 December 2010.
Profit performance for the period was in line with management’s expectations. The year was marked by the successful Admission to AIM in October 2010, raising funds to enable the implementation of an acquisition strategy to complement organic growth. The Board continues to explore several prospective acquisition opportunities and will provide further updates when appropriate.
Instem has continued to increase its dominance in the Early Development Safety Assessment market adding several significant new customers to its roster. Additionally the Company has made further advances into the broader early development IT applications market through the launch in October 2010 of its new product suite, Centrus™. Several of the world’s leading Contract Research Organisation and pharmaceutical businesses have been early adopters of Centrus, which the Directors’ believe bodes well for future progress.
Final results for the year ended 31 December 2010 will be announced on 22 March 2011.
Phil Reason, CEO of Instem Life Science Systems plc, commented, “2010 has been an outstanding year for Instem. We are delighted to have been able to welcome new shareholders in October through our Admission to AIM and to have made progress with both our organic and acquisitive growth strategies. We look forward to giving a further update on progress in our preliminary results announcement in March.”
For further information, please contact:
|Phil Reason, CEO||+44 (0) 1785 825600|
|Nigel Goldsmith, CFO|
|N+1 Singer (Nominated Adviser & Broker)||+44 (0) 20 7496 3000|
|Wallbrook Financial PR||Tel: +44 (0) 20 7933 8000|
|Paul Cornelius||or firstname.lastname@example.org|
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.
To learn more about Instem solutions and its mission, please visit instem.com.